As Canada’s flu season collides with record strep A cases and ongoing COVID-19 concerns, a new study is shedding light on our understanding of respiratory immune responses.
Breakthrough in hemophilia A treatment: Sobi’s ALTUVOCT receives EU marketing authorization
Sobi® today announced the European Commission has granted Marketing Authorization for ALTUVOCT™ (efanesoctocog alfa), for the treatment and prevention of bleeds and perioperative prophylaxis in hemophilia